Effect of Vitamin D and ω-3 Fatty Acid Supplementation on Risk of Age-Related Macular Degeneration: An Ancillary Study of the VITAL Randomized Clinical Trial.

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc.

However, evidence from randomized trials is limited.

Who Took Part

The study group was 25,871 men.

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

Participants included 25 871 men and women in the US.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

As a double-blind Vitamin D, K2, Magnesium and Zinc study, the assignments were hidden from both participants and investigators until the end.

Some men received a placebo instead of Vitamin D, K2, Magnesium and Zinc, giving a reference point.

Randomization was from November 2011 to March 2014, and study pill-taking ended as planned on December 31, 2017.

What Was Measured

The subject headings attached to it are Dietary Supplements, Disease Progression, Fatty Acids, Omega-3, Incidence, Macular Degeneration, Prognosis and United States.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 25,871 men.

With several hundred people or more, it is a fairly large study for this kind of research.

Results are reported in around 10 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2020 (JAMA ophthalmology), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.